Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: Epoprostenol
Trade Name: Flolan
Date Designated: 09/25/1985
Orphan Designation: Treatment of primary pulmonary hypertension.
Orphan Designation Status: Designated/Approved
Glaxo Wellcome Inc.
5 Moore Drive
Research Triangle Park, North Carolina 27709
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: Epoprostenol
Trade Name: Flolan
Marketing Approval Date: 09/20/1995
Approved Labeled Indication: Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.
Exclusivity End Date: 09/20/2002 
Exclusivity Protected Indication* :  
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-